Study of HSK41959 with standard therapy for MTAP-deleted solid tumors
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an investigational drug called HSK41959 combined with standard cancer therapy for people whose tumors have a specific genetic change (MTAP deletion). The goal is to see if the combination is safe and works better against advanced solid tumors, including non-small cell lung cancer and pancreatic cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer is advanced or has spread and has an MTAP deletion (a specific genetic change in the tumor).
- You have not had prior treatment with drugs targeting the MAT2A or PRMT5 pathway (e.g., certain investigational medicines).
- You have at least one tumor that can be measured on scans (per RECIST).
- You are in generally good health (ECOG 0–1) and able to do daily activities.
- You are willing to provide a tumor sample for testing, if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug for people with advanced solid tumors or lymphoma that has not responded to standard treatments and has a specific genetic change (loss of MTAP or CDKN2A genes). The drug is taken by mouth and may work by targeting cancer cells with this change.
This trial tests a new experimental drug (HSK41959) for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and effective for tumors that no longer respond to standard treatments.
This Phase 1 trial studies MRTX1719, a new medicine, in solid tumors that have a missing MTAP gene (MTAP deletion). It aims to find the safest dose and check how the drug affects the tumor.
This trial tests an experimental pill called SY-9453 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if it is safe and how the body processes it. It may be an option if you have tried standard treatments without success.
This trial tests a new drug called HSK46256 for people with advanced solid tumors that have not responded to standard treatments. The drug may target cancer cells with certain genetic changes, and the study aims to find the best dose and see how well it works.
This trial tests an experimental drug called BMS-986504, given alone or with other drugs, for people with advanced solid tumors that have a specific genetic change called a homozygous MTAP deletion. It may be an option if standard treatments are no longer working or aren't available.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.